Arcus Announces Clinical Trial Collaboration With AstraZeneca To Evaluate Casdatifan

(RTTNews) - Arcus Biosciences, Inc. (RCUS), Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC. https://www.nasdaq.com/articles/arcus-announces-clinical-trial-collaboration-astrazeneca-evaluate-casdatifan